文献速递神经肿瘤神经重症

儿童中枢神经系统肿瘤幸存者迟发性神经系统疾病的纵向评估:儿童癌症幸存者研究报告

Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report.
PubMed 文献 · Neuro Oncol · 2018-01-01

儿童中枢神经系统肿瘤5年幸存者(n=1876)纵向评估显示,从诊断后5年到30年,癫痫累积发病率从27%升至41%,运动障碍从21%升至35%,听力损失从9%升至23%,均显著高于兄弟姐妹。颅脑放疗、卒中、肿瘤复发和脑膜瘤与新发神经功能缺损独立相关。

要点

  • 儿童中枢神经系统肿瘤幸存者从诊断后5年到30年,癫痫累积发病率从27%升至41%,运动障碍从21%升至35%,听力损失从9%升至23%。
  • 与兄弟姐妹相比,幸存者癫痫风险HR为12.7(95%CI 9.6-16.7),运动障碍HR为7.6(95%CI 5.8-9.9),听力损失HR为18.4(95%CI 13.1-25.9)。
  • 额叶放疗剂量≥50 Gy与运动障碍相关(HR 2.0,95%CI 1.2-3.4),卒中与运动障碍强烈相关(HR 14.9,95%CI 10.4-21.4)。

核心结论

  • 儿童中枢神经系统肿瘤幸存者终生面临新发不良神经系统事件风险,且风险高于兄弟姐妹。
  • 颅脑放疗、卒中、肿瘤复发和脑膜瘤发生与迟发性不良神经系统后遗症独立相关。

研究设计与样本

  • 儿童癌症幸存者研究(Childhood Cancer Survivor Study)的纵向评估,纳入1876名儿童中枢神经系统肿瘤5年幸存者,从诊断起中位随访23.0年(范围5.1-38.9),末次评估中位年龄30.3岁(范围6.1-56.4)。
  • 采用多变量回归估计风险比(HR)和95%置信区间(CI)。

主要发现

  • 从诊断后5年到30年,癫痫累积发病率从27%升至41%,运动障碍从21%升至35%,听力损失从9%升至23%。
  • 与兄弟姐妹相比,幸存者癫痫风险HR为12.7(95%CI 9.6-16.7),运动障碍HR为7.6(95%CI 5.8-9.9),听力损失HR为18.4(95%CI 13.1-25.9)。
  • 额叶放疗剂量≥50 Gy与运动障碍相关(HR 2.0,95%CI 1.2-3.4)。
  • 运动障碍风险增加还与肿瘤复发(HR 2.6,95%CI 1.8-3.8)、脑膜瘤发生(HR 2.3,95%CI 0.9-5.4)和卒中(HR 14.9,95%CI 10.4-21.4)相关。
  • 癫痫风险在肿瘤复发(HR 2.3,95%CI 1.6-3.2)、脑膜瘤(HR 2.6,95%CI 1.1-6.5)和卒中(HR 2.0,95%CI 1.1-3.4)情况下加倍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Survivors of childhood central nervous system (CNS) tumors experience high rates of treatment-related neurologic sequelae. Whether survivors continue to be at increased risk for new events as they age is unknown. METHODS: Adverse neurologic health conditions in 5-year survivors of CNS tumors from the Childhood Cancer Survivor Study (n = 1876) were evaluated longitudinally at a median 23.0 years from diagnosis (range, 5.1-38.9), median age at last evaluation 30.3 years (range, 6.1-56.4). Multivariable regression estimated hazard ratios (HRs) and 95% CIs. RESULTS: From 5 to 30 years post diagnosis, cumulative incidence increased for seizures from 27% to 41%, motor impairment 21% to 35%, and hearing loss 9% to 23%. Risks were elevated compared with siblings (eg, seizures HR: 12.7; 95% CI: 9.6-16.7; motor impairment HR: 7.6; 95% CI: 5.8-9.9; hearing loss HR: 18.4; 95% CI: 13.1-25.9). Regional brain doses of radiation therapy were associated with development of new deficits (eg, frontal ≥50 Gy and motor impairment HR: 2.0; 95% CI: 1.2-3.4). Increased risk for motor impairment was also associated with tumor recurrence (HR: 2.6; 95% CI: 1.8-3.8), development of a meningioma (HR: 2.3; 95% CI: 0.9-5.4), and stroke (HR: 14.9; 95% CI: 10.4-21.4). Seizure risk was doubled by recurrence (HR: 2.3; 95% CI: 1.6-3.2), meningioma (HR: 2.6; 95% CI: 1.1-6.5), and stroke (HR: 2.0; 95% CI: 1.1-3.4). CONCLUSIONS: CNS tumor survivors remain at risk for new-onset adverse neurologic events across their lifespans at a rate greater than siblings. Cranial radiation, stroke, tumor recurrence, and development of meningioma were independently associated with late-onset adverse neurologic sequelae.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Wells EM, Ullrich NJ, Seidel K, et al. Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. Neuro Oncol. 2018. PMID: 29016809. doi:10.1093/neuonc/nox148

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。